This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Becker, R. C. Search for Related Content PubMed Articles by Becker, R. C. Related Collections Acute coronary syndromes Pathophysiology Arterial thrombosis Related Article

Editorials

Advancing Biomarker Science in the 21st Century

Richard C. Becker, MD

From the Divisions of Cardiology and Hematology, Duke University School of Medicine, Duke Clinical Research Institute, Durham, NC.

Correspondence to Richard C. Becker, MD, Duke University Medical Center, 2400 Pratt St, DUMC 3850, Durham, NC 27705. E-mail becke021@mc.duke.edu

Key Words: Editorials • arteriosclerosis • endothelium-derived factors • biomarkers

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 

"Do something wonderful, people may imitate it."

— —Albert Schweitzer

One of the primary objectives of scientific investigation in medicine is to inform patient care. The creative, imaginative, and intelligent study of advanced biomarkers, including genes, transcripts, proteins, and metabolic byproducts, may hold the key to redefining human disease and achieving optimal clinical outcomes. Given the global interest, overarching relevance, and inherent complexity, the most pertinent question becomes, "what is required of the scientific and medical communities to advance meaningfully the discipline of biomarker science in the 21st century?"

Article see p 14

In this issue of the Circulation: Cardiovascular Interventions, Derer et al¹ introduce vitronectin as an independent predictor of both early (30-day) and late (6-month) major adverse cardiovascular events after percutaneous coronary intervention (PCI) with or without stenting. Patients with a baseline serum vitronectin level 49.7 mg/mL (representing the upper quartile) experienced death, myocardial infarction, or urgent target-vessel revascularization at a 3-fold higher rate than patients in the 3 lower quartiles. Will vitronectin become an established part of the armamentarium for periprocedural risk assessment? Will it one day assume the lofty status of troponin as a readily available and widely implemented measurement tool for clinicians?

Cardiac-specific troponin is considered the prototypical biomarker for several reasons. It is detectable in very low concentrations under normal conditions; it increases rapidly, predictably, and for a well-defined duration after myoctye necrosis; and it identifies patients at risk for subsequent cardiovascular events and those in whom antithrombotic pharmacotherapy and PCI offer the . . . [Full Text of this Article]

Related Article

Vitronectin Concentrations Predict Risk in Patients Undergoing Coronary Stenting

Wolfgang Derer, Elliot S. Barnathan, Erdal Safak, Prasheen Agarwal, Harald Heidecke, Martin Möckel, Michael Gross, Cemil Oezcelik, Rainer Dietz, and Ralf Dechend
Circ Cardiovasc Interv 2009 2: 14-19. [Abstract] [Full Text] [PDF]